Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Published in The New England journal of medicine • Nov 11, 2023
Authors:,,
Lincoff AM
Brown-Frandsen K
Colhoun HM
Abstract
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown.Methods In...
Finding related papers...
Discussions
(0)No comments yet
Be the first to share your thoughts!